Iconovo AB

Iconovo AB is a Swedish company focused on developing inhaled medicinal products, partnering with international pharmaceutical firms to deliver innovative respiratory therapies. Founded in 2013 in Lund, Sweden, Iconovo AB specializes in creating inhalation products. The company was established by Carl Forslund, Mats Johansson, Mårten Rittfeldt, and Orest Lastow. Johan Wäborg serves as the CEO.

Iconovo has successfully completed one funding round, raising EUR 2. 3 million on June 19, 2017, which represents the total amount raised. Iconovo specializes in the development of inhaled medicinal products, collaborating with international pharmaceutical companies to create innovative solutions for respiratory therapies. The company's core offerings include patented dry powder inhalers and in-house formulation services, enabling the development of inhalation products for both new pharmaceuticals and generic medicines.

These inhalers are designed to optimize the delivery of active pharmaceutical ingredients, addressing respiratory conditions such as asthma and COPD. Iconovo's products cater to pharmaceutical companies globally, including markets in North America, Europe, and Asia, facilitating faster market entry while maintaining high quality and efficacy standards. In 2022, Iconovo reported a revenue of EUR 1,697,799, while facing an EBITDA loss of EUR 4,108,264. The company's revenue model is based on strategic partnerships with pharmaceutical companies, primarily operating on a B2B basis, including collaborations that provide patented inhaler technology and formulation services to clients, who then develop their inhalation products for market release.

Iconovo plans to expand its product line by developing new inhalation devices and aims to enter additional markets across North America and Asia by 2025. The recent funding of EUR 2. 3 million will be utilized to support these initiatives, enabling the company to enhance its product offerings and accelerate its market expansion efforts.